AIDS and Cancer Specimen Resource (ACSR)

描述（由申请人提供）：美国国家癌症研究所（NCI）于1994年建立了艾滋病和癌症标本资源（ACSR），以支持临床注释生物标本的收集和专家保存，用于多学科研究，将实验室基础科学与临床、行为和流行病学研究联系起来。在过去的19年里，ACSR为成功的转化研究提供了基础，这依赖于持续获取高质量的、有良好注释的生物标本。通过在标本采集和维护方法方面的广泛专业知识的发展，包括标本稳定性和全功能加班，该公司实现了这一目标。ACSR对艾滋病毒转化研究至关重要，为研究人员扩大服务，并制定实践，以补充全球艾滋病毒研究人员的创新实验方向。自2008年以来，ACSR已经储存了5万多份生物标本，并向全世界的科学家分发了1万多份生物标本。ACSR还制定了独特的计划，提供各级项目咨询和研究人员培训，以协助标本选择和告知生物储存程序，从而确保适当处理和使用有价值的生物标本进行研究。当前ACSR下完成的工作将被利用和过渡，以实现新ACSR的具体目标：1)开发和维护ACSR基础设施，使ACSR的整体使命（支持当前和未来的艾滋病毒/艾滋病恶性肿瘤研究趋势）有效转化为持续的功能性项目；2)提供科学领导，扩大资源的利用和相关性；3)获取、维护和分发各种高质量和注释良好的生物标本；4)通过ACSR服务支持国内和国际的倡议、项目、计划和收藏。为了实现这些目标，我们将把目前的ACSR重组为一个单一的多站点ACSR，在主席办公室（OC）的指导下，由中央操作和数据协调中心（CODCC）管理，由高级调查员共同领导。Michael McGrath和Sylvia Silver，代表加州大学旧金山分校和乔治华盛顿大学（GW）区域生物标本库（RBR）。UCSF和GW这两个原始的rbr占ACSR总库存（500,000多个标本）的80%，在过去五年中提供给研究人员的标本占90%。拟议的ACSR还将通过将亚利桑那大学、图森大学和贝勒医学院的附属项目过渡到新的rbr来增加价值。ACSR将继续发展和简化操作，以纳入最先进的库存系统，以及提高标本生存能力的新技术和方法。ACSR是一个充满活力的实体，它使用创新和新颖的方法来应对流行病和研究方向的变化，并处于有利地位，可以继续支持艾滋病毒研究的当前和未来趋势，这将对全世界艾滋病毒恶性肿瘤的诊断和管理产生积极影响。

DESCRIPTION (provided by applicant): The National Cancer Institute (NCI) established the AIDS and Cancer Specimen Resource (ACSR) in 1994 to support the collection and expert preservation of clinically-annotated biospecimens for multidisciplinary research, bridging laboratory basic science with clinical, behavioral, and epidemiological studies. For the past 19 years, the ACSR has provided the foundation for successful translational research reliant on consistent access to high-quality well-annotated biospecimens. It has accomplished this via development of extensive expertise in methods for specimen collection and maintenance including specimen stability and full functionality overtime. The ACSR remains crucial to HIV-translational research, expanding services to researchers, and instituting practices to complement innovative new experimental directions by global HIV investigators. Since 2008, the current grant cycle, ACSR banked over 50,000 and distributed over 10,000 biospecimens to scientists worldwide. ACSR has also developed unique programs, offering project consultation and researcher training at all levels that assist with specimen choice and inform about biorepository procedures, thus ensuring appropriate handling and use of valuable biospecimens for research. The work accomplished under the current ACSR will be leveraged and transitioned to achieve the Specific Aims for the new ACSR to: 1) develop and maintain the ACSR infrastructure that allows efficient translation of the overall ACSR mission (to support current and future trends in HIV/AIDS malignancy research) to an ongoing functional program 2) provide scientific leadership, expand utilization and relevance of the resource; 3) acquire, maintain and distribute a diverse collection of high-quality and well-annotated biospecimens and; 4) support initiatives, projects, programs and collections, both national and international through ACSR services. To accomplish these aims we will restructure the current ACSR to a single multisite ACSR, under the direction of the Office of the Chairs (OC) and administered by the Central Operations and Data Coordinating Center (CODCC) to be led by senior investigators in a shared leadership role, Drs. Michael McGrath and Sylvia Silver, representing the continuing UCSF and George Washington University (GW) Regional Biospecimen Repositories (RBR). The two original RBRs, UCSF and GW, account for > 80% of the overall ACSR inventory (500,000+ specimens) and for supplying 90% of the specimens disbursed to researchers in the past five years. The proposed ACSR also will add value through transitioning affiliate programs at the University of Arizona, Tucson, and Baylor College of Medicine to new RBRs. The ACSR will continue to evolve and streamline operations to incorporate a state of the art inventory system, and new technologies and methods to improve specimen viability. The ACSR is a dynamic entity that has used innovative and novel approaches to meet changes in the epidemic and research directions, and is well positioned to continue support of current and future trends in HIV research that will have a positive impact on diagnosis and management of HIV-malignancies worldwide.